Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions
Explore this paper's citation graph
Summary
Clinical implementation of algorithms based upon cardiac imaging and several non-imaging biomarkers can prevent cardiac morbidity and mortality associated with the use of cardiotoxic cancer therapies.
- Type
- review
- Published
- 2017-04-03
- Cited by
- 100
- References
- 86
- Access
- Open access
- OpenAlex
- https://openalex.org/W2604555357
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:19055967
Keywords
Medicine, Cardiotoxicity, Cancer, Trastuzumab, Heart failure
References
- Trastuzumab and breast cancer.
- Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer.
- Fluoropyrimidine-associated cardiotoxicity: revisited
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.
- Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
- Is echocardiography reliable for monitoring the adverse cardiac effects of chemotherapy?
- 5-Fluorouracil cardiotoxicity.
- Congestive heart failure in patients treated with doxorubicin
- Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
- A Reevaluation of the Costs of Heart Failure and Its Implications for Allocation of Health Resources in the United States
- Risk factors for doxorubicin-induced congestive heart failure.
- PD-1 Blockers.
- Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.
- High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
- Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
- The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
- Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health.
- Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics.
- Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin.
Cited by
- Cardiotoxicity of cancer chemotherapy in clinical practice
- Microscopic evaluation of the ventricular tissue using stereological and Voronoi tessellation methods: Application on doxorubicin-induced cardiotoxicity in rats.
- Lung cancer as a cardiotoxic state: a review
- Aspalathin Reverts Doxorubicin-Induced Cardiotoxicity through Increased Autophagy and Decreased Expression of p53/mTOR/p62 Signaling
- Cardiotoxicity of immune checkpoint inhibitors
- Low dose radiation prevents doxorubicin-induced cardiotoxicity
- Cardiovascular disease incidence in adolescent and young adult cancer survivors: a retrospective cohort study
- Cardiotoxicity of Anticancer Therapeutics
- Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy
- Bioinformatics identification of potential candidate blood indicators for doxorubicin-induced heart failure
- EXERCISE TO PREVENT ANTHRACYCLINE-BASED CARDIOTOXICITY IN INDIVIDUALS WITH BREAST OR HEMATOLOGICAL CANCERS
- Heart toxicity from breast cancer radiotherapy
- The Assessment of Left Ventricle Function and Subclinical Atherosclerosis in Patients with Acute Myeloid Leukemia
- CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping.
- Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States.
- Attenuation of doxorubicin-induced cardiotoxicity in a human in vitro cardiac model by the induction of the NRF-2 pathway.
- Low-Dose Radiation Prevents Chemotherapy-Induced Cardiotoxicity
- Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment
- An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy
- Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients
Related papers
- The mechanistic insights of the arrhythmogenic effect of trastuzumab.
- Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer: Chavez-MacGregor M, Zhang N, Buchholz TA, et al (Univ of Texas MD Anderson Cancer Ctr, Houston) J Clin Oncol 31:4222-4228, 2013§
- Trastuzumab cardiotoxicity: from clinical trials to experimental studies
- Trastuzumab (Herceptin®) induced cardiotoxicity in the elderly population: Do we need to re-assess prescribing practices?
- The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
- Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors
- Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer
- Trastuzumab-induced cardiomyopathy.
- Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab